Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inhibitor 13
- Development stage
- Preclinical
- Lead developer
- Texas A&M University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Inhibitor 13 is a small molecule inhibitor of the Eleven-Nineteen-Leukemia (ENL) YEATS domain, identified by researchers at Texas A&M University. It was discovered using a NanoBRET system designed to evaluate the cellular permeability and potency of ENL inhibitors. The compound exhibits high metabolic stability and potent antiproliferative effects against mixed-lineage leukemia (MLL)-fusion cell lines. In preclinical studies, inhibitor 13 demonstrated significant survival benefits in acute myeloid leukemia (AML) xenografted mice. It served as the structural basis for the development of the optimized candidate SR-C-107 (R).
02
Targets
ENL YEATS (ENL YEATS domain)
Beyond the preview
Go deeper on inhibitor 13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inhibitor 13.